Revance therapeutics investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of revance therapeutics, inc. - rvnc

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of revance therapeutics, inc. (nasdaqgm: rvnc) to crown laboratories, inc. under the terms of the proposed transaction, shareholders of revance will receive $6.66 in cash for each share of revance that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate, or.
RVNC Ratings Summary
RVNC Quant Ranking